- Report
- May 2023
- 190 Pages
Global
From €2202EUR$2,450USD£1,912GBP
- Report
- November 2023
- 135 Pages
Global
From €3595EUR$4,000USD£3,121GBP
- Report
- January 2024
- 250 Pages
Global
From €7146EUR$7,950USD£6,203GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2921EUR$3,250USD£2,536GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2472EUR$2,750USD£2,146GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2472EUR$2,750USD£2,146GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2472EUR$2,750USD£2,146GBP
- Report
- August 2022
- 181 Pages
Global
From €6741EUR$7,500USD£5,852GBP
- Report
- August 2022
- 218 Pages
Global
From €6741EUR$7,500USD£5,852GBP
- Report
- May 2024
- 130 Pages
Global
From €3595EUR$3,999USD£3,120GBP
- Report
- May 2024
- 134 Pages
Global
From €3595EUR$3,999USD£3,120GBP
- Report
- February 2023
- 143 Pages
North America
From €3101EUR$3,450USD£2,692GBP
- Report
- August 2024
- 93 Pages
Global
From €3500EUR$4,171USD£3,145GBP

Treprostinil is a drug used to treat respiratory diseases such as pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It is a prostacyclin analogue, meaning it works by mimicking the effects of prostacyclin, a naturally occurring hormone in the body that helps to regulate blood pressure in the lungs. Treprostinil is administered through a variety of methods, including oral tablets, subcutaneous injections, and inhalation. It is also available in a topical form for the treatment of Raynaud's phenomenon.
Treprostinil is a relatively new drug, having been approved by the FDA in 2002. It is used to treat a variety of respiratory diseases, including PAH, CTEPH, and Raynaud's phenomenon. It is also used to treat other conditions such as sickle cell anemia and cystic fibrosis.
The treprostinil market is a growing one, with many companies offering products and services related to the drug. Some of these companies include United Therapeutics, Actelion Pharmaceuticals, GlaxoSmithKline, and Pfizer. Show Less Read more